<DOC>
	<DOCNO>NCT02503605</DOCNO>
	<brief_summary>Biosimilar drug marketing recombinant FSH treatment infertility another step simplify fertility treatment , make easy manage accessible patient . Taking mind argument , study propose determine equivalence term biological effectiveness ovarian stimulation protocol biosimilar recombinant FSH stimulation protocol vs. urinary FSH oocyte donation program .</brief_summary>
	<brief_title>Biosimilar Versus Urinary Gonadotropins</brief_title>
	<detailed_description>Biosimilar product drug `` like '' biotechnological origin innovative biological medicine market patent expire . These drug intend achieve therapeutic benefit biological medicinal resembles . Because similarity active substance formulation , intend demonstrate equivalence biosimilar medicine recombinant FSH FSH urinary origin term fitness . The investigator ' main objective perform non-inferiority trial biosimilar recombinant FSH product compare conventional ovarian stimulation protocol urinary FSH relation number oocytes retrieved number metaphase II oocytes .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Patients age 1835 year meet criterion entry oocyte donor program go undergo control ovarian stimulation Patient basal antral count &gt; 20 follicle total &lt; 6 antral follicle per ovary Patients comorbidities , opinion investigator , may interfere treatment ovarian stimulation The presence ovarian cyst judgment investigator would interfere stimulation may pose risk donor BMI &lt; 18 kg / m2 BMI &gt; 30 kg / m2 Severe hypersensitivity drug similar structure</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Biosimilar</keyword>
	<keyword>ovarian stimulation</keyword>
	<keyword>oocyte donor</keyword>
</DOC>